WAVE Life Sciences Ltd.
WVE
Health Care
2
exclusion reasons
1 theme
WAVE Life Sciences Ltd. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Wave Life Sciences Ltd. is a biotechnology company developing stereopure oligonucleotide therapeutics, a class of drugs that requires extensive preclinical animal testing for regulatory approval. The company's pipeline, including candidates like WVE-N531 and WVE-120102, is dependent on animal models to demonstrate safety and efficacy before advancing to human clinical trials. This reliance on animal testing is a core, non-negotiable component of its business model for bringing new drugs to market.
The company is explicitly listed by Cruelty Free Investors as a firm that conducts animal testing. While specific internal testing protocols are not detailed in public filings, the nature of its investigational products and the regulatory pathway for oligonucleotide therapeutics necessitate the use of animals. There is no public commitment from Wave Life Sciences to adopt alternative testing methods or to reduce and replace animal use in its research and development process.
Wave Life Sciences Ltd. is a clinical-stage genetic medicines company whose drug development pipeline relies on animal testing to advance therapeutic candidates. The company's public research disclosures, including papers in the Journal of Nucleic Acids Research and its 2021 financial report, explicitly highlight data from "a multitude of in vitro and in vivo (animal) studies." This indicates animal models are integral to its preclinical research and regulatory submission process.
As a biopharmaceutical firm developing oligonucleotide therapies for neurological and metabolic diseases, Wave Life Sciences operates in a sector where animal testing is currently mandated by global health authorities for safety and efficacy evaluation prior to human trials. The company's collaborations with major pharmaceutical partners like Takeda and GSK further involve preclinical work that necessitates animal data. This places the company within the exclusion category for commissioning and relying on animal testing as part of its core product development activities.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.